Startups

Neuracle Medical Technology

Shanghai, China

Neurotechnology business with current parent 博睿康技术（上海）股份有限公司 and Changzhou origins. Supplies commercial EEG/neuroscience products and develops NEO interfaces. NEO’s Shanghai medical-device registrant is a related, distinct entity. Founders Xu Honglai and Huang Xiaoshan. IPO fundraising target is not proceeds.

Founded 2011

Team

Ding JianfengSales VP / director

Gong ChanghuiR&D director

Huang XiaoshanCofounder

Li JiabinCFO / board secretary

Liu TaoDirector / deputy general manager

Xu HonglaiCofounder

Investments

CN¥250M2024-11-08	Guofu Linghang, Pudong Venture Capital, Lianxin Technology, Detong Hexin, Yuanke Innovation, Yuanke II
$—Unknown date	Baidu Ventures

team@apexlogos.ai2 days ago
RELATED
team@apexlogos.ai2 days ago
BCI research snapshot, reviewed 2026-10-06. Company identity: NeuracleMedicalTechnology. This is the pre-import evidence dossier; historical statements about database absence or review are archival. Unverified claims remain research leads, not validated facts. Part 1/1 # Neuracle / 博睿康 Research accessed: **2026-10-06**. Review draft; no database changes. Original source: user-pasted BCI.INTEL Company Tracker (47 entries). ## Identity and scope Verified neurotechnology business, not the Korean Neuracle Science or similarly named IT vendors. Historical **博睿康科技（常州）股份有限公司**, founded **November 2011** by **胥红来 Xu Honglai and 黄肖山 Huang Xiaoshan** in Changzhou; [government company profile](https://kjc.changzhou.gov.cn/html/kjc/2023/JLCCKNME_0224/7313.html) and [government periodical](https://kjj.changzhou.gov.cn/uploadfile/kjj/2023/0308/20230308100145221.pdf). Current parent **博睿康技术（上海）股份有限公司**, Shanghai, per [June 2026 IPO prospectus](https://pdf.dfcfw.com/pdf/H2_AN202606111823465014_1.pdf). NEO device registrant is the related **博睿康医疗科技（上海）有限公司**, not automatically the same legal record. Official site [neuracle.cn](https://www.neuracle.cn/), intermittently inaccessible. Commercial neuroscience/EEG products and semi-invasive NEO implant development are distinct product lines. ## Audit of pasted claims | Pasted claim | Finding | |---|---| | Shanghai HQ | More precise: Shanghai parent/device registrant, with Changzhou origin. | | CEO omitted | Xu Honglai chairman/general manager; Huang Xiaoshan vice-chair/deputy general manager, per 2026 prospectus. Historical founder-CEO stories may use different role dates. | | Funding undisclosed | Documented financing and IPO filing exist; unknown complete historical total. | | NEO semi-invasive BCI | **NMPA approval announced 2026-03-13** for implanted hand-motion compensation system; extradural approach. [Shanghai regulator](https://yjj.sh.gov.cn/zjyw/20260313/04985a5fbe284e9c806ff5f370cb00b2.html), [NMPA](https://www.nmpa.gov.cn/zhuanti/cxylqx/cxylqxlm/20260313134742156.html). | | Active | Regulatory approval and 2026 IPO review support operating status. | ## Investments and ownership | Date | Amount / type | Counterparties and evidence | |---|---|---| | 2015 / 2018 / 2019 / 2021 | Four historical rounds; amounts and individual-round allocation unspecified | Government profile names HSG/Sequoia, Kaifeng Venture, China Control, WI Harper, Rongtuo, Zhongguancun Development, Baidu Ventures collectively. [Government periodical](https://kjj.changzhou.gov.cn/uploadfile/kjj/2023/0308/20230308100145221.pdf). **Do not distribute all investors across all four rounds.** | | **2024-11-08 agreement**; closings Dec2024 and May2025 | **RMB250M equity**, two RMB125M tranches of one agreement | Legal funds **国孚领航 Guofu Linghang, 浦东创投 Pudong VC, 联新科技 Lianxin Technology, 德同合心 Detong Hexin, 元科创新 Yuanke Innovation, 元科贰号 Yuanke II**. [Primary prospectus](https://pdf.dfcfw.com/pdf/H2_AN202606111823465014_1.pdf). No verified lead designation. | | Date ambiguous: investor page published March2024, distributed Apr2026 | **RMB60M**, historical financing lead only; exclude from sum pending transaction-date/duplication review | WI Harper syndicated announcement names China Control, China Development Fund, China Development Frontier, Baidu Ventures: [primary WI Harper article dated March2024](https://wiharper.com/brain-computer-interface-company-neuracle-raises-rmb-60-million/), [syndication](https://www.publicnow.com/view/3F17BE3433FE6FBEDB51AE0B7739EB7D7DB6D599). | | June2026 IPO application | **RMB2.5bn fundraising target**, not received capital | STAR-market review in progress, not completed IPO; [application tracking](https://www.stcn.com/ipo/detail/3692.html). | A direct founder interview describes an early RMB1M angel stake before moving to Changzhou in2012, approximately2015 RMB15M angel financing and **2019 RMB60M Series A**. [Primary interview reported by The Paper](https://www.thepaper.cn/newsDetail_forward_32819169). These chronology facts help identify the WI Harper RMB60M item as possibly a republished historical round; verify before adding it separately. No defensible complete historical equity total. Prospectus includes additional November2025 financing that requires a separately checked transaction extraction before import. Equity cash proceeds must not be confused with nominal registered-capital increases. ## Founders and public team | Person | Role and time basis | Profile / evidence | Direct profile-picture URL | |---|---|---|---| | Xu Honglai (胥红来) | Cofounder; current chairman / general manager | [2026 issuer prospectus](https://pdf.dfcfw.com/pdf/H2_AN202606111823465014_1.pdf); [government founder feature, picture immediately before named caption](https://kjc.changzhou.gov.cn/html/kjc/2023/JLCCKNME_0224/7313.html) | https://kjc.changzhou.gov.cn/uploadfile/kjc/2023/0224/20230224111016_47826.jpg | | Huang Xiaoshan (黄肖山) | Cofounder; current vice-chair / deputy general manager | [2026 issuer prospectus](https://pdf.dfcfw.com/pdf/H2_AN202606111823465014_1.pdf) | Unavailable: no reliably identified direct portrait URL established; do not use unrelated Neuracle Science staff | | Liu Tao (刘涛) | Director / deputy general manager | [2026 issuer prospectus](https://pdf.dfcfw.com/pdf/H2_AN202606111823465014_1.pdf) | Unavailable: no reliably identified direct portrait URL established; do not use unrelated Neuracle Science staff | | Li Jiabin (李嘉斌) | CFO / board secretary | [2026 issuer prospectus](https://pdf.dfcfw.com/pdf/H2_AN202606111823465014_1.pdf) | Unavailable: no reliably identified direct portrait URL established; do not use unrelated Neuracle Science staff | | Gong Changhui (龚昌辉) | R&D director | [2026 issuer prospectus](https://pdf.dfcfw.com/pdf/H2_AN202606111823465014_1.pdf) | Unavailable: no reliably identified direct portrait URL established; do not use unrelated Neuracle Science staff | | Ding Jianfeng (丁剑峰) | Sales VP / director | [2026 issuer prospectus](https://pdf.dfcfw.com/pdf/H2_AN202606111823465014_1.pdf) | Unavailable: no reliably identified direct portrait URL established; do not use unrelated Neuracle Science staff | ## Company profile image Company logo/profile image **unresolved**. Official source page: https://www.neuracle.cn/ . Direct website attempts timed out or were blocked, and indexed government/founder pages did not expose a confidently assigned logo. The Xu portrait was recovered from the government article’s actual `img src` immediately before his named founder caption. Do not invent a CDN path or import the Korean Neuracle Science logo. This is a material media completeness flag for review. ## Adex match and review decision No Org name match in read-only `%neuracle%` search. Proposed **NeuracleMedicalTechnology**, but select the exact parent versus NEO device subsidiary deliberately before import. Verified company; **hold media and legal-entity mapping**, with chronology/funding-detail checks. Do not treat IPO target as money raised. Team names/roles from prospectus, founders corroborated independently by government history. Media validation2026-10-06: Xu Honglai government photograph returned HTTP200 image/jpeg. Company logo remains unavailable; government agency header logo must not be substituted for company branding.